|
T4081 |
MPTP hydrochloride
|
MPTP-hydrochloride |
Apoptosis
,
Dopamine Receptor
|
|
MPTP hydrochloride is a precursor of MPP+, a dopamine neurotoxin with blood-brain barrier permeability. MPTP hydrochloride is toxic to dopaminergic neurons, which can lead to Parkinson's disease, and is widely used in th... |
|
T71195 |
mPTP-IN-22
|
|
|
|
mPTP-IN-22 is a novel mitochondrial permeability transition pore (mptp) inhibitor |
|
T71193 |
Jak2-IN-7j
|
|
|
|
Jak2-IN-7j is a selective Jak2 inhibitor which demonstrates a time-dependent knock-down of pSTAT5, which is a downstream target of Jak2. |
|
T4491 |
LMPTP INHIBITOR 1 hydrochloride
|
LMPTP INHIBITOR 1 hydrochloride (1908414-82-3(free base)) |
Phosphatase
|
|
LMPTP INHIBITOR 1 hydrochloride is a selective inhibitor of low molecular weight protein tyrosine phosphatase ( LMPTP ), with an IC 50 of 0.8 μM for LMPTP-A. |
|
T41298 |
LMPTP INHIBITOR 1 dihydrochloride
|
|
Phosphatase
|
|
LMPTP Inhibitor 1 Dihydrochloride is a compound selectively targeting low molecular weight protein tyrosine phosphatase (LMPTP), exhibiting potent inhibitory activity with an IC50 value of 0.8 μM for LMPTP-A. |
|
T79479 |
MptpB-IN-2
|
|
Antibiotic
|
|
MptpB-IN-2 (compound 20), a selective inhibitor for mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB), exhibits half maximal inhibitory concentrations (IC50) of 0.64 μM for MptpB, 4.06 μM for MptpA, and 4... |
|
T73120 |
MptpB-IN-1
|
|
|
|
MptpB-IN-1 is a potent, orally active MptpB inhibitor that targets the Mycobacterium tuberculosis protein-tyrosine-phosphatase B (MptpB), a secreted virulence factor evading host antimicrobial mechanisms. It effectively ... |
|
T15241 |
ER-000444793
|
|
Others
,
Mitochondrial Metabolism
|
|
ER-000444793 is a potent mitochondrial permeability transition pore (mPTP) opening inhibitor and it also inhibits mPTP (IC50: 2.8 μM). |
|
T26686 |
AV-101
|
L-4-Cl-KYN,L-4-chlorokynurenine,4-Cl-KYN,4ClKYN,4-Chlorokynurenine,(S)-4-Chlorokynurenine |
NMDAR
|
|
AV-101 (4-Cl-KYN) , a prodrug antagonist at the glycine site of the NMDA receptor, has antidepressant activity and reduces levodopa-induced dyskinesia in MPTP monkeys. |
|
T10404 |
ATP synthase inhibitor 1
|
|
ATPase
|
|
ATP synthase inhibitor 1 is an inhibitor of the c subunit of the F1/FO-ATP synthase complex. It inhibits mitochondrial permeability transition pore (mPTP) opening and does not affect ATP levels. |
|
T9169 |
MPP+ iodide
|
|
Mitochondrial Metabolism
,
Autophagy
|
|
MPP+ iodide, the metabolite of a neurotoxin MPTP, causes symptom of Parkinson's disease (PD) in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ induces dopamine transporter (DAT) ex... |
|
T61268 |
Vutiglabridin
|
HSG4112 |
Phosphatase
|
|
Vutiglabridin (HSG4112) is a novel and safe modulator of PON2, a racemic compound. vutiglabridin is an optimized structural analogue of Glabridin and is superior to Glabridin in terms of weight loss and chemical stabilit... |
|
T38034 |
MAO-IN-M30 dihydrochloride
|
M 30 dihydrochloride |
Monoamine Oxidase
|
|
MAO-IN-M30 dihydrochloride (M 30 dihydrochloride) is a potent and brain selective monoamine oxidase (MAO) inhibitor (EC50 values are 37 and 57 nM for MAO-A and MAO-B, respectively). Also an iron chelator with antioxidant... |
|
T27959 |
LY503430
|
LY-503430,LY 503430 |
|
|
LY503430 is a AMPA receptor potentiator with oral activity. LY503430 has both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP. |
|
T24645 |
Piroheptine HCl
|
Piroheptine Hydrochloride,Trimol |
|
|
Piroheptine HCl is an agent of anticholinergic that acts by inhibiting dopamine uptake and completely preventing loss of striatal dopamine in MPTP-treated mice. |
|
T33450 |
ML 23
|
ML-23,ML23 |
|
|
ML 23 is a melatonin analogue in the treatment and management of Parkinson's disease. ML-23 is a potential clinical candidate for the treatment of PD, and the present study has been undertaken to determine the efficacy o... |
|
T38202 |
PAQ
|
|
|
|
PAQ is a neuroprotective agent. It protects dopaminergic neurons from cell death without inhibiting glial cell proliferation in a rat midbrain culture model of Parkinson's disease when used at a concentration of 10 μM. P... |
|
TP2019 |
[D-Ala2]-GIP (human)
|
|
|
|
Highly potent GIP receptor agonist (EC50 = 630 ± 119 pM). Displays equivalent cAMP stimulating properties and improved resistance to enzymatic degradation compared to native GIP in cells expressing wild type GIP receptor... |
|
T36176 |
AMK (hydrochloride)
|
|
|
|
AMK is an active metabolite of the neurohormone melatonin .1,2,3,4It is formed from melatoninviathe metabolic intermediate AFMK that is then deformylated by catalase or formamidase.5,6AMK scavenges singlet oxygenin vitro... |
|
T37847 |
Zonisamide-13C2,15N
|
Zonisamide-13C2,15N |
|
|
Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide is an antiepileptic agent.1 It selectively inhibits the repeated firing of sodium channels ... |
|
T83894 |
4A7C-301-Nurr1 Agonist
|
4A7C-301-Nuclear Receptor-Related 1 |
|
|
The compound 4A7C-301-Nurr1 agonist is a specific agonist for the nuclear receptor-related 1 (Nurr1). By binding to the Nurr1 ligand-binding domain with an IC50 value of 48.22 nM, it enhances the transcriptional activity... |
|
T83726 |
Tat-βsyn-degron TFA
|
|
|
|
Tat-βsyn-degron, an α-synuclein knockdown peptide, integrates three domains: the HIV-1 Tat plasma membrane transduction domain, an α-synuclein binding domain (βsyn) representing amino acids 36-45 of β-synuclein, and a pr... |
|
T37297 |
Ru360
|
|
|
|
Ru360, an oxygen-bridged dinuclear ruthenium amine complex, is a selective mitochondrial calcium uptake inhibitor. Ru360 potently inhibits Ca2+ uptake into mitochondria with an IC50 of 0.184 nM. Ru360 binds to mitochondr... |
